ArticleHealth science reports2026
RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: New respiratory syncytial virus (RSV) preventative programs are launching globally. Our Australian jurisdiction implemented RSV monoclonal antibody provision via pediatric and perinatal hospitals for highest risk neonates and infants. The aim of this study was to monitor the implementation and utilization of nirsevimab and palivizumab in a cohort of infants at increased risk who were program recipients in Victorian hospitals in 2024 and provide evidence and operational context for future programs. Methods: In this observational cohort study, suitable participants at each site were identified by checking the drug administration records for receipt of nirsevimab and/or palivizumab. Follow-up of all infants was via the hospital electronic medical record (EMR), with relevant administration information as well as any subsequent respiratory encounters (defined by testing for respiratory pathogens) at either Monash Children's Hospital or the Royal Children's Hospital, Melbourne. This study was descriptive and exploratory, and no formal effectiveness or comparative analyses were undertaken. Results: In total, 430 infants received RSV preventatives at five hospital sites throughout Victoria. In total, 54% of infants who received RSV preventatives were premature (< 37 weeks gestation); 45% were < 32 weeks gestation and four infants (2 pre-term; 2 term) experienced breakthrough infection. Conclusion: Without a national program combining maternal and infant preventatives, hospital-level targeted programs can protect infants at highest risk of severe RSV and reduce admissions; we recommend biopharmaceutical support for these targeted initiatives over large population-wide programs that have not met cost-effectiveness criteria-this 2024 approach informed Australia's 2025 RSV program. Findings will inform ongoing RSV special-risk initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.